11:16 AM EDT, 07/31/2024 (MT Newswires) -- Grifols ( GRFS ) unit GigaGen said Wednesday it received the US Food and Drug Administration's clearance for its investigational new drug application to launch a phase 1 trial of its GIGA-2339 drug to treat hepatitis B virus infection.

The trial will help evaluate the safety and tolerability of GIGA-2339 in patients with confirmed HBV infection, the company said.

GigaGen plans to initiate the trial later this year.

Price: 7.81, Change: +0.06, Percent Change: +0.77